CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
05 Jun 2024
05 Jun 2024
Historique:
received:
21
12
2023
accepted:
18
04
2024
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
5
6
2024
Statut:
aheadofprint
Résumé
Sjögren's disease (SjD) is a chronic, systemic autoimmune disease with no approved disease-modifying therapies. Dazodalibep (DAZ), a novel nonantibody fusion protein, is a CD40 ligand antagonist that blocks costimulatory signals between T and B cells and antigen-presenting cells, and therefore may suppress the wide spectrum of cellular and humoral responses that drive autoimmunity in SjD. This study was a phase 2, randomized, double-blinded, placebo (PBO)-controlled trial of DAZ with a crossover stage in two distinct populations of participants with SjD. Population 1 had moderate-to-severe systemic disease activity and population 2 had an unacceptable symptom burden and limited systemic organ involvement. All participants had a diagnosis of SjD, with 21.6% and 10.1% having an associated connective tissue disease (rheumatoid arthritis or systemic lupus erythematosus) in populations 1 and 2, respectively. The remaining participants would be considered as having primary Sjögren's syndrome. The primary endpoint for population 1 (n = 74) was the change from baseline in the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index at day 169. The primary endpoint for population 2 (n = 109) was the change from baseline in the European League Against Rheumatism Sjögren's Syndrome Patient Reported Index at day 169. The primary endpoints (least squares mean ± standard error) were achieved with statistical significance for both population 1 (DAZ, -6.3 ± 0.6; PBO, -4.1 ± 0.6; P = 0.0167) and population 2 (DAZ, -1.8 ± 0.2; PBO, -0.5 ± 0.2; P = 0.0002). DAZ was generally safe and well tolerated. Among the most frequently reported adverse events were COVID-19, diarrhea, headache, nasopharyngitis, upper respiratory tract infection, arthralgia, constipation and urinary tract infection. In summary, DAZ appears to be a potential new therapy for SjD and its efficacy implies an important role for the CD40/CD40 ligand pathway in its pathogenesis. ClinicalTrials.gov identifier: NCT04129164 .
Identifiants
pubmed: 38839899
doi: 10.1038/s41591-024-03009-3
pii: 10.1038/s41591-024-03009-3
doi:
Banques de données
ClinicalTrials.gov
['NCT04129164']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Mavragani, C. P. Mechanisms and new strategies for primary Sjögren’s syndrome. Annu. Rev. Med. 68, 331–343 (2017).
doi: 10.1146/annurev-med-043015-123313
pubmed: 28099084
Retamozo, S. et al. Systemic manifestations of primary Sjögren’s syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clin. Exp. Rheumatol. 37, 97–106 (2019).
pubmed: 31464664
Mariette, X. & Criswell, L. A. Primary Sjögren’s syndrome. N. Engl. J. Med. 378, 931–939 (2018).
doi: 10.1056/NEJMcp1702514
pubmed: 29514034
Ramos-Casals, M. et al. Characterization of systemic disease in primary Sjögren’s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 54, 2230–2238 (2015).
doi: 10.1093/rheumatology/kev200
pubmed: 26231345
pmcid: 6281074
Leone, M. C. et al. The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo 69, 93–100 (2017).
doi: 10.4081/reumatismo.2017.1032
pubmed: 28933131
McCoy, S. S. & Baer, A. N. Neurological complications of Sjögren’s syndrome: diagnosis and management. Curr. Treatm. Opt. Rheumatol. 3, 275–288 (2017).
doi: 10.1007/s40674-017-0076-9
pubmed: 30627507
pmcid: 6322693
Uhlig, T., Kvien, T. K., Jensen, J. L. & Axéll, T. Sicca symptoms, saliva and tear production, and disease variables in 636 patients with rheumatoid arthritis. Ann. Rheum. Dis. 58, 415–422 (1999).
doi: 10.1136/ard.58.7.415
pubmed: 10381485
pmcid: 1752918
Manoussakis, M. N. et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum. 50, 882–891 (2004).
doi: 10.1002/art.20093
pubmed: 15022331
McCoy, S. S. et al. A comprehensive overview of living with Sjögren’s: results of a National Sjögren’s Foundation survey. Clin. Rheumatol. 41, 2071–2078 (2022).
doi: 10.1007/s10067-022-06119-w
pubmed: 35257256
pmcid: 9610846
Cornec, D. et al. Severe health-related quality of life impairment in active primary Sjögren’s syndrome and patient-reported outcomes: data from a large therapeutic trial. Arthritis Care Res. 69, 528–535 (2017).
doi: 10.1002/acr.22974
Hammitt, K. M., Naegeli, A. N., van den Broek, R. W. M. & Birt, J. A. Patient burden of Sjögren’s: a comprehensive literature review revealing the range and heterogeneity of measures used in assessments of severity. RMD Open 3, e000443 (2017).
doi: 10.1136/rmdopen-2017-000443
pubmed: 28955493
pmcid: 5604724
Ambrus, J. L., Suresh, L. & Peck, A. Multiple roles for B-lymphocytes in Sjogren’s syndrome. J. Clin. Med. 5, 87 (2016).
doi: 10.3390/jcm5100087
pubmed: 27740602
pmcid: 5086589
Ohlsson, M., Szodoray, P., Loro, L. L., Johannessen, A. C. & Jonsson, R. CD40, CD154, Bax and Bcl-2 expression in Sjögren’s syndrome salivary glands: a putative anti-apoptotic role during its effector phases. Scand. J. Immunol. 56, 561–571 (2002).
doi: 10.1046/j.1365-3083.2002.01168.x
pubmed: 12472667
Dimitriou, I. D., Kapsogeorgou, E. K., Moutsopoulos, H. M. & Manoussakis, M. N. CD40 on salivary gland epithelial cells: high constitutive expression by cultured cells from Sjögren’s syndrome patients indicating their intrinsic activation. Clin. Exp. Immunol. 127, 386–392 (2002).
doi: 10.1046/j.1365-2249.2002.01752.x
pubmed: 11876766
pmcid: 1906327
van Kooten, C. & Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol. 67, 2–17 (2000).
doi: 10.1002/jlb.67.1.2
pubmed: 10647992
Grewal, I. S. & Flavell, R. A. A central role of CD40 ligand in the regulation of CD4
doi: 10.1016/0167-5699(96)10030-X
pubmed: 8854557
Verstappen, G. M., Pringle, S., Bootsma, H. & Kroese, F. G. M. Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. Nat. Rev. Rheumatol. 17, 333–348 (2021).
doi: 10.1038/s41584-021-00605-2
pubmed: 33911236
pmcid: 8081003
Goules, A. et al. Elevated levels of soluble CD40 ligand (sCD40L) in serum of patients with systemic autoimmune diseases. J. Autoimmun. 26, 165–171 (2006).
doi: 10.1016/j.jaut.2006.02.002
pubmed: 16621447
Vivino, F. B. et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch. Intern. Med. 159, 174–181 (1999).
doi: 10.1001/archinte.159.2.174
pubmed: 9927101
Papas, A. S. et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J. Clin. Rheumatol. 10, 169–177 (2004).
doi: 10.1097/01.rhu.0000135553.08057.21
pubmed: 17043506
Fife, R. S. et al. Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. Arch. Intern. Med. 162, 1293–1300 (2002).
doi: 10.1001/archinte.162.11.1293
pubmed: 12038948
Karnell, J. L., Rieder, S. A., Ettinger, R. & Kolbeck, R. Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond. Adv. Drug Deliv. Rev. 141, 92–103 (2019).
doi: 10.1016/j.addr.2018.12.005
pubmed: 30552917
Boumpas, D. T. et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 48, 719–727 (2003).
doi: 10.1002/art.10856
pubmed: 12632425
Robles-Carrillo, L. et al. Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice. J. Immunol. 185, 1577–1583 (2010).
doi: 10.4049/jimmunol.0903888
pubmed: 20585032
Karnell, J. L. et al. A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity. Sci. Transl. Med. 11, eaar6584 (2019).
doi: 10.1126/scitranslmed.aar6584
pubmed: 31019027
Kivitz, A. et al. The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis. RMD Open 9, e003317 (2023).
doi: 10.1136/rmdopen-2023-003317
pubmed: 37541743
pmcid: 10407378
Fox, R. I. & Fox, C. M. Sjögren syndrome: why do clinical trials fail? Rheum. Dis. Clin. North Am. 42, 519–530 (2016).
doi: 10.1016/j.rdc.2016.03.009
pubmed: 27431352
Fox, R. I., Fox, C. M., Gottenberg, J. E. & Dörner, T. Treatment of Sjögren’s syndrome: current therapy and future directions. Rheumatology 60, 2066–2074 (2021).
doi: 10.1093/rheumatology/kez142
pubmed: 31034046
Seror, R. et al. EULAR Sjogren’s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren’s syndrome. Ann. Rheum. Dis. 69, 1103–1109 (2010).
doi: 10.1136/ard.2009.110619
pubmed: 19561361
Seror, R. et al. EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren’s syndrome. Ann. Rheum. Dis. 70, 968–972 (2011).
doi: 10.1136/ard.2010.143743
pubmed: 21345815
Tocoian, A. et al. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. Lupus 24, 1045–1056 (2015).
doi: 10.1177/0961203315574558
pubmed: 25784719
Vermersch, P. et al. Inhibition of CD40L with frexalimab in multiple sclerosis. N. Engl. J. Med. 390, 589–600 (2024).
doi: 10.1056/NEJMoa2309439
pubmed: 38354138
Fisher, B. A. et al. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren’s syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. Lancet Rheumatol. 2, e142–e152 (2020).
doi: 10.1016/S2665-9913(19)30135-3
pubmed: 38263652
Nicholson, S. M. et al. The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br. J. Pharmacol. 177, 1061–1076 (2020).
doi: 10.1111/bph.14897
pubmed: 31648370
pmcid: 7042118
Seror, R. et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann. Rheum. Dis. 75, 382–389 (2016).
doi: 10.1136/annrheumdis-2014-206008
pubmed: 25480887
Bechman, K., Yates, M., Norton, S., Cope, A. P. & Galloway, J. B. Placebo response in rheumatoid arthritis clinical trials. J. Rheumatol. 47, 28–34 (2020).
doi: 10.3899/jrheum.190008
pubmed: 31043548
Zhang, W., Robertson, J., Jones, A. C., Dieppe, P. A. & Doherty, M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann. Rheum. Dis. 67, 1716–1723 (2008).
doi: 10.1136/ard.2008.092015
pubmed: 18541604
Griffiths, N. et al. Content validity of Sjögren’s syndrome symptom diary and functional assessment of chronic illness therapy–fatigue in patients with Sjögren’s. Rheumatol. Ther. 9, 1559–1574 (2022).
doi: 10.1007/s40744-022-00489-y
pubmed: 36152275
pmcid: 9561476
Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D. & Reis, B. L. Reliability and validity of the Ocular Surface Disease Index. Arch. Ophthalmol. 118, 615–621 (2000).
doi: 10.1001/archopht.118.5.615
pubmed: 10815152